Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

Recruiting now

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.

Key facts

Study ID

NCT06221800

Run by

University of California, Irvine

People needed

82

Starts

2024-01-31

Expected to finish

2026-12-01

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Advanced/Metastatic non-small cell lung cancer NSCLC patients.
• 2. The patient himself/herself must be 18 years of age on day of signing informed consent.
• 3. The subject has signed the informed consent form.
• 4. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.
• 5. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration

You may not qualify if…

• 1. Those subjects who are determined clinically unstable of the participation of this study as determined by the PI or treating physician will be excluded and asked to focus on their treatment.

Where it is running

• Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.